Kyverna Therapeutics Presents Updated Phase 1 Data for Miv-cel in Progressive Multiple Sclerosis

Kyverna Therapeutics presented updated Phase 1 data for its autologous CD19-targeting CAR T-cell therapy, miv-cel (KYV-101), at the MS Toronto 2026 meeting, focusing on its application in progressive multiple sclerosis. The therapy aims to deplete B-cells to reset the immune system, potentially providing a durable, single-dose treatment. The company has received RMAT designation for miv-cel and plans to share further updates on its multiple sclerosis strategy by early 2027.